tbuckley/cabot-search huggingface dataset:
Abstract 17563: Rescan Reproducibility of Quantitative Coronary Plaque Burden From Low Radiation Dose High-pitch Coronary Ct Angiography
Authors: Kristian Altern Oevrehus, Annika Schuhbaeck, Damini Dey, Stephan Achenbach, Mohamed Marwan, Hans Erik Bøtker, Bjarne Linde Nørgaard
Journal: Circulation (2013)

Introduction:  Coronary Computed Tomography angiography (CTA) can characterize coronary atherosclerotic plaque components as calcified and non-calcified. Quantitative measurements of coronary plaque burden by CTA might play a role in serial studies to determine disease progression or response to medical therapies. Rescan reproducibility of such quantitative measurements from low-radiation dose CTA has not been previously assessed.   Purpose:  To evaluate the interscan and interobserver variability for coronary plaque volume assessment using low radiation dose high-pitch spiral acquisition coronary CT angiography (CTA).   Methods:  Two experienced observers independently evaluated coronary CTA datasets from 50 consecutive patients undergoing two 128-slice dual source CT scans within 12 days. Mean (±SD) estimated radiation exposure was 1.5 mSv ±0.2 mSv per scan. Observers evaluated coronary plaque volumes using validated software (AutoPlaq) on a per plaque level and per patient level, and reproducibility was assessed using Bland-Altman analyses, spearman′s rho correlation and paired t-test.   Results:  There were no significant mean differences in interscan or interobserver non-calcified plaque volumes, or in patient non-calcified or total plaque volumes (Table).   Conclusion:  Low radiation dose high-pitch coronary CTA, with semi-automated quantitative measurements, allow reproducible characterization and measurement of coronary atherosclerotic plaque burden from serial scans.
Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004
Authors: C. Montagut Viladot, A. Bardelli, T. Tuxen Poulsen, R. Dienstmann, M. Kragh, S. Kopetz, K. Koefoed, F. Ciardiello, C. Ding, J. Vidal, J. Clausell-Tormos, G. Siravegna, T. Lindsted, M.W. Pedersen, G. Rospo, G. Argilés Martinez, P. Nadler, I.D. Horak, J. Tabernero
Journal: Annals of Oncology (2017)
Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer (Chloe trial)
Authors: T. Shien, A. Shimomura, Y. Uemura, H. Kato, M. Kitada, Y. Kikawa, E. Shiba, T. Yoshida, T. Morimoto, T. Toyama, T. Aihara, H. Mukai
Journal: Annals of Oncology (2017)
Aspirin for Prevention of Preeclampsia
Authors: A. Atallah, E. Lecarpentier, F. Goffinet, M. Doret-Dion, P. Gaucherand, V. Tsatsaris
Journal: Drugs (2017)

Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia.
Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results
Authors: R. Bahleda, F.S. Braiteh, A.S. Balmanoukian, I. Braña, F.S. Hodi, L. Garbo, B. Liu, L. Molinero, C. O'Hear, X. Shen, A.D. Colevas
Journal: Annals of Oncology (2017)
Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel (nab-P) to capecitabine and oxaliplatin (CAPOX) as first line treatment of advanced esophagogastric adenocarcinoma (EGAC) (ACTION study)
Authors: S. Schokker, D.J. Van Zoen, S.O. Van der Woude, S.L. Meijer, R.A.A. Mathot, M.F. Bijlsma, M.G.H. Van Oijen, C.J.A. Punt, H.W.M. Van Laarhoven
Journal: Annals of Oncology (2017)
Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla MSI Test
Authors: G. Maertens, B. De Craene, E. Rondelez, K. Peeters, L. Vandenbroeck, L. Van Puymbroeck, G. Vandercruyssen, E. Sablon
Journal: Annals of Oncology (2017)
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
Authors: Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P Hughes, Neil P. Shah, Hagop M. Kantarjian
Journal: Journal of Clinical Oncology (2016)

7013 Background: The approved tyrosine kinase inhibitor (TKI)ponatinib is potently active against native and resistant BCR-ABL, including T315I. Methods: The pivotal PACE trial (NCT01207440) evaluated ponatinib (starting dose 45 mg/d) in pts with chronic myeloid leukemia (CML) or Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) refractory to dasatinib or nilotinib, or with T315I. Dose reductions were recommended in Oct '13 due to observed arterial occlusive events (AOEs). Efficacy and safety at 4 yrs, as well as by yr for chronic phase (CP) CML pts, are reported (data as of 3 Aug '15). Exposure-adjusted incidence rates of new AOEs are reported as the no. of events/100 pt-yrs. Results: Of 449 pts, 59% received ≥ 3 prior TKIs. At analysis, 30% of pts (median follow-up 37.3, range 0.1–58.5 mo) and 41% (110/270) of CP-CML pts (48.2, 0.1–58.5 mo) remained on study. Responses continued to deepen over time (Table) despite dose reductions. Estimated 4-yr rates for PFS, OS, and maintenance of MCyR and MMR were 56%, 77%, 82% and 61%, respectively. For advanced phase pts, the estimated 4-yr OS was 51%; median OS for blast phase/Ph+ALL pts: 6.9 mo (95% CI, 5.0-9.2). Common (in ≥ 30% of pts) TEAEs were thrombocytopenia 44%, abdominal pain 43%, rash 42%, constipation 37%, headache 37%, dry skin 36%, fatigue and hypertension 30%. AOE rate/serious AOE rate was 23%/19%, including cardio- 13%/9%, cerebro- 9%/7%, and peripheral-vascular 9%/7%. Of pts with AOEs (n = 104), 38% remained on study. Exposure-adjusted incidence rates of new AOEs fell after the first 2 yrs: 15.5 yr 1, 15.7 yr 2, 10.4 yr 3, and 9.6 yr 4. Nearly 2-yrs after recommended dose reductions, 87% (114/131) and 74% (70/95) of CP-CML pts were estimated to maintain MCyR and MMR, respectively, and 8% (6/75) of all dose-reduced pts without a prior AOE on trial had an AOE. Conclusions: After 4 yrs,heavilypretreated pts continue to show deep and lasting responses on ponatinib, and ~2 yrs post recommended dose reductions, maintenance of response is high, and the incidence of newly occurring AOEs has decreased. Clinical trial information: NCT01207440.Cumulative response rates (%) with ponatinib in CP-CML pts (n = 267, efficacy evaluable). MCyR CCyR MMR / MR4.5 Yr 1 55 51 30 / 9 Yr 2 58 53 36 / 16 Yr 3 59 53 39 / 22 Yr 4 59 54 39 / 23
Couverture vaccinale dans l’Union Européenne
Authors: N Guérin, C Roure
Journal: Eurosurveillance (1997)

Les 15 pays de l’Union Europeenne ont ratifie l’objectif n°5 de la Sante pour tous en l’an 2000, du bureau regional de l’OMS pour l’Europe, qui s’enonce comme suit : iEn l’an 2000, il ne devrait plus avoir de cas de poliomyelite, diphterie, tetanos neonatal, rougeole, oreillons et rubeole congenitale dans la region et il devrait y avoir une reduction importante et continue de l’incidence et des consequences nefastes d’autres maladies transmissibles, en particulier l’infection par le VIH ».
Cold-forceps avulsion with adjuvant snare-tip soft coagulation (CAST) is an effective and safe strategy for the management of non-lifting large laterally spreading colonic lesions
Authors: David Tate, Farzan Bahin, Lobke Desomer, Mayenaaz Sidhu, Vikas Gupta, Michael Bourke
Journal: Endoscopy (2017)

Abstract Background and aims Non-lifting large laterally spreading colorectal lesions (LSLs) are challenging to resect endoscopically and often necessitate surgery. A safe, simple technique to treat non-lifting LSLs endoscopically with robust long-term outcomes has not been described. Methods In this single-center prospective observational study of consecutive patients referred for endoscopic mucosal resection (EMR) of LSLs ≥ 20 mm, LSLs not completely resectable by snare because of non-lifting underwent standardized completion of resection with cold-forceps avulsion and adjuvant snare-tip soft coagulation (CAST). Scheduled surveillance colonoscopies were performed at 4 – 6 months (SC1) and 18 months (SC2). Primary outcomes were endoscopic evidence of adenoma clearance and avoidance of surgery. The secondary outcome was safety. Results From January 2012 to October 2016, 540 lifting LSLs (82.2 %) underwent complete snare excision at EMR. CAST was required for complete removal in 101 non-lifting LSLs (17.8 %): 63 naïve non-lifting lesions (NNLs; 62.7 %) and 38 previously attempted non-lifting lesions (PANLs; 37.3 %). PANLs were smaller (P &lt; 0.001) and more likely to be non-granular (P = 0.001) than the lifting LSLs. NNLs were of similar size (P = 0.77) and morphology (P = 0.10) to the lifting LSLs. CAST was successful in all cases and adverse events were comparable to lifting LSLs resected by complete snare excision. Recurrence at SC1 was comparable for PANLs (15.2 %) and lifting LSLs (15.3 %; P = 0.99), whereas NNLs recurred more frequently (27.5 %; P = 0.049); however, surgery was no more common for either type of non-lifting LSL than for lifting LSLs. Conclusion CAST is a safe, effective, and surgery-sparing therapy for the majority of non-lifting LSLs. It is easy to use, inexpensive, and does not require additional equipment. Clinicaltrials.gov: NCT 2000141
Hot water extracts from broccoli sprouts trigger induction of carcinogen-detoxification enzymes in prostate tissues.
Authors: Angela J. Caruso, Srinivasan Yegnasubramanian, Xiaohui Lin, Thomas W. Kensler, William G. Nelson
Journal: Cancer Research (2004)

3149  Intake of vegetables, particularly cruciferous vegetables, reduces prostate cancer risks.1 Sulforaphane, an isothiocyanate present in cruciferous vegetables, may protect against cancer development by inducing the expression of carcinogen-detoxification enzymes, such as glutathione S- transferases (GSTs).2,3 Upon consumption of glucosinolate compounds in cruciferous vegetables, isothiocyanates can be released during chewing via exposure of the glucosinolates to the plant enzyme myrosinase (thioglucoside glucohydrolase). In order to test whether sulforaphane and other isothiocyanates in broccoli sprouts can elevate the expression of chemoprotective enzymes in prostate tissues, both purified sulforaphane and a hot water extract of broccoli sprouts (broccoli sprout tea) were administered to adult male Fisher 344 rats, prone to develop prostate cancer when exposed to heterocyclic amine carcinogens,4 by gastric gavage. To monitor carcinogen-detoxification enzyme expression, RNA- and protein-containing extracts were prepared from liver, intestine, spleen and prostate tissues recovered 48 hours after treatment. GST activity was assessed using a CDNB assay.5 The expression of mRNAs encoding other chemoprotective enzymes was evaluated via hybridization to Affymetrix expression arrays. The results were that while both sulforaphane and broccoli sprout tea triggered increases in GST activity in the liver and the intestine, in a dose dependent manor, only the broccoli sprout tea caused increased GST activity in the prostate. mRNA expression profiling confirmed an induction of transcripts encoding chemoprotective enzymes in the different tissues. These findings suggest that consumption of cruciferous vegetables, containing glucosinolates, may effectively augment carcinogen defenses both in major metabolic organs, such as the liver and the intestine, as well as in cancer-prone organs, such as the prostate. References: 1Cohen JH et al. J. Natl. Cancer Inst. 92:61-68 (2000). 2Fahey JW et al. Proc. Natl. Acad. Sci., 94:10367-10372 (1997). 3Talalay P et al. Adv Enzyme Regul., 43:121-134 (2003). Shirai T et al. Cancer Res. 57:195-198 (1997). 5Habig WH et al. J. Biol. Chem. 249:7130-7139 (1974).
Elevated Brain Amyloid in Cognitively Normal Individuals—Reply
Authors: Michael C. Donohue, Paul S. Aisen
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
Authors: R. Schlenk, H. Dombret, S. Amadori, P. Montesinos, M. Levis, M.A. Sekeres, J. Cortes, A. Perl, O. Zernovak, D. Mires, N. Ge, H. Zhang, J. Hanyok, S. Macintyre, S. Gökmen, K. Kobayashi, H. Erba
Journal: Annals of Oncology (2017)
Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients
Authors: M. Blanco Codesido, A. Calvo Ferrandiz, S. Lopez-Tarruella Cobo, R. Alvarez, Y. Jerez, I. Marquez Rodas, S. Perez Ramirez, A. Muñoz, A. Calles, P. Sabin Domínguez, C. López, A.C. Picornell, B. Puente, C. Rubio, M. Herencia, T. Massarrah, M. Martin Jimenez
Journal: Annals of Oncology (2017)
Distinct Angiogenic Changes during Carcinogenesis Defined by Novel Label-Free Dark-Field Imaging in a Hamster Cheek Pouch Model
Authors: Fangyao Hu, Hannah Martin, Amy Martinez, Jeffrey Everitt, Alaattin Erkanli, Walter T. Lee, Mark Dewhirst, Nimmi Ramanujam
Journal: Cancer Research (2017)

Abstract There remain gaps in knowledge concerning how vascular morphology evolves during carcinogenesis. In this study, we imaged neovascularization by label-free dark-field microscopy of a 7,12-Dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch model of oral squamous cell carcinoma (SCC). Wavelength-dependent imaging revealed distinct vascular features at different imaging depths and vessel sizes. Vascular tortuosity increased significantly in high-risk lesions, whereas diameter decreased significantly in hyperplastic and SCC lesions. Large vessels preserved the same trends seen in the original images, whereas small vessels displayed different trends, with length and diameter increasing during carcinogenesis. On the basis of these data, we developed and validated a classification algorithm incorporating vascular features from different vessel masks. Receiver operator curves generated from the classification results demonstrated high accuracies in discriminating normal and hyperplasia from high-grade lesions (AUC &amp;gt; 0.94). Overall, these results provided automated imaging of vasculature in the earliest stages of carcinogenesis from which one can extract robust endpoints. The optical toolbox described here is simple, low-cost and portable, and can be used in a variety of health care and research settings for cancer prevention and pharmacology research. Cancer Res; 77(24); 7109–19. ©2017 AACR.
Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis
Authors: Bastien Joubert, Catherine Chapelon-Abric, Lucie Biard, David Saadoun, Sophie Demeret, Didier Dormont, Matthieu Resche-Rigon, Patrice Cacoub
Journal: JAMA Neurology (2017)

Prognostic factors are lacking in neurosarcoidosis (NS), and the association of immunosuppressive treatments with outcomes are unclear.To identify prognostic factors of and analyze the association of immunosuppressive treatment with relapse of NS.In this retrospective study, a cohort of 234 patients fulfilled the diagnostic criteria for NS in a tertiary referral center in Paris, France, from January 1, 1990, through December 31, 2015. The median follow-up was 8 years (range, 2 months to 23 years).All neurologic and extraneurologic data and treatments were analyzed. Functional outcomes measured by the absolute value and the variation from baseline of the Expanded Disability Status Scale (EDSS) score at 60 months after the diagnosis, overall survival, and relapse-free survival (RFS) were assessed. Analyses were stratified by the period of NS diagnosis (1990-1999 vs 2000-2015).The 234 patients undergoing assessment included 117 women (50.0%) and 117 men (50.0%); median age was 42 years (interquartile range, 32-53 years). The probable 10-year survival rate was 89% (95% CI, 84%-94%). Older age (hazard ratio [HR] per 10 years, 1.64; 95% CI, 1.19-2.27; P = .003), peripheral nervous system involvement (HR, 6.75; 95% CI, 2.31-19.7; P < .001), and higher baseline EDSS score (HR per point, 1.21; 95% CI, 1.06-1.39; P = .005) were associated with mortality. The estimated 10-year RFS rate was 14% (95% CI, 9%-22%) for all relapses and 28% (95% CI, 20%-38%) for neurologic relapses. Encephalic involvement was associated with shorter neurologic RFS (HR, 2.35; 95% CI, 1.44-3.83; P < .001). A lower risk for relapse was associated with cyclophosphamide (HR, 0.26; 95% CI, 0.11-0.59; P = .001), methotrexate sodium (HR, 0.47; 95% CI, 0.25-0.87; P = .02), and infliximab (HR, 0.16; 95% CI, 0.02-1.24; P = .08) treatments. Follow-up was greater than 60 months in 160 patients (68.4%). An elevated baseline EDSS score (odds ratio [OR] per point, 1.92; 95% CI, 1.55-2.37; P < .001), tobacco use (OR, 3.64; 95% CI, 1.36-9.73; P = .01), encephalic symptoms (OR, 3.04; 95% CI, 1.11-8.38; P = .03), and less than 4 extraneurologic sarcoidosis localizations (OR, 3.06; 95% CI, 1.04-8.98; P = .04) were associated with an EDSS value of at least 2.5 at 60 months. Encephalic involvement (16 of 17 patients [94.1%]; P = .008) and peripheral nervous system involvement (5 of 17 patients [29.4%]; P = .03) were associated with worsening of the EDSS score at 60 months.This study identifies putative factors affecting morbidity and mortality in patients with NS. Immunosuppressive therapies (ie, intravenous cyclophosphamide, methotrexate, and infliximab) in these patients may be associated with lower relapse rates.
The application of liquid biopsies in metastatic salivary gland cancer to identify candidate therapeutic targets
Authors: R. Metcalf, S. Mohan, S. Hilton, J. Pierce, J. Hudson, G. Betts, A. Chaturvedi, J. Homer, H. Leong, P. Schofield, D. Rothwell, G. Brady, C. Dive
Journal: Annals of Oncology (2017)
Clinical and immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam
Authors: J.P. Marquez-Manriquez, J.A.M. Briseno, K. Quayle, L.M. Fernandez, I.R. Barajas, G. Torres-Montano, F.A. Durazo-Bustamante, A. Durazo-Acuna, L-A. Rangel-Reyna, D. Lopez-Hernandez, A. Rodriguez-Jasso, M-A. Trujillo-Acosta, E. Ramos-Garcia, S. Icedo-Zamora, P.A.L. Diaz
Journal: Annals of Oncology (2017)
Significance of Fecal Occult Blood Test Followed By Colonoscopy for Asymptomatic Dasatinib-Induced Hemorrhagic Colitis (CML1501 Study)
Authors: Satoshi Nishiwaki, Matsuyoshi Maeda, Masahiro Yamada, Shingo Okuno, Yasuhiko Harada, Kotaro Suzuki, Shingo Kurahashi, Fumihiro Urano, Shozo Okamura, Isamu Sugiura
Journal: Blood (2016)
Epidémie de Escherichia coli O157 en Ecosse, novembre-décembre 1996
Authors: J M Cowden
Journal: Eurosurveillance (1997)

Le vendredi 22 novembre 1996 apres-midi, le departement de sante publique du Health Board de Lanarkshire fut informe de 15 cas possibles d’infection a Escherichia coli O157 (dont cinq avaient ete confirmes microbiologiquement) parmi les residents de la ville de Wishaw dans la region centrale de l’Ecosse. Tous les cas avaient soit consomme de la viande froide ou des sandwichs a la viande provenant d’un boucher local, soit mange des tranches de viande en sauce fournies par le meme boucher lors d’un repas paroissial le 17 novembre. A ce stade, on pouvait penser que l’association entre les cas et la viande de ce boucher etait une coincidence. De plus, le boucher avait gagne recemment le prix du meilleur boucher de boeuf Ecossais de l’annee. Toutefois, au vu de la severite de l’infection, le boucher fut prie d’interrompre la vente de produits a base de viande cuite a compter du 23 novembre au matin.
Abstract 16619: Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease in Male Veterans: is it Still Continuous and Graded?
Authors: Xuan-Mai T Nguyen, Yuk-Lam Ho, Rebecca J Song, Jacqueline Honerlaw, Jason L Vassy, David R Gagnon, Kelly Cho, Peter W Wilson
Journal: Circulation (2016)

Introduction:  The MRFIT Screenees project, conducted before the widespread use of statins, showed that greater serum cholesterol levels were associated with an increased risk of coronary heart disease (CHD) death. We examined outpatient serum cholesterol levels and 6 year CHD death in male Veterans in the VA Healthcare system between 2002-2007.   Methods:  Analyses were restricted to subjects free of cancer, not on statins, and without a history of a myocardial infarction at baseline. Cox models were used to estimate hazard ratios (HR) for CHD death. CHD death was defined using I20-I25 ICD-10 codes from the National Death Index.   Results:  Among 1,261,762 subjects we observed a J-shaped relationship between cholesterol categories and age-adjusted hazard ratios for White and Black males (Table 1). CHD death was more than doubled in the highest cholesterol group for both Whites (HR: 2.15) and Blacks (HR: 2.43) compared to the second group. After multivariable adjustment for age, diabetes, major mental health diagnosis, systolic blood pressure (SBP) and smoking status, we found that the HR for CHD death among the low cholesterol group was attenuated, suggesting that some of the increased mortality observed was explained by comorbidities. In the same model, the effect of SBP on CHD death was also noteworthy: 5% increase risk of CHD death for SBP>140 mmHg (vs ≤140 mmHg) among Whites and 37% increase risk of CHD death among Blacks. The HR for CHD death among the highest cholesterol group for Whites and Blacks remained doubled (HR: 2.30 and 2.16, respectively).   Conclusions:  In contrast to the MRFIT Screenees project, data from a large sample of Veterans receiving medical care do not demonstrate a continuous, graded relationship between cholesterol and 6-year CHD death. Rather, they support a J-shaped relationship where cholesterol levels under 180mg/dl also confer greater risk for CHD death.